The concept of "patient needs first" and the proud achievement that half of its clinical departments rank first in the United States have always been a story in the medical field.
In 20 15, Mayo cooperated with Koyo Capital, one of the largest investment funds in Asia, and established "Huimei Medical Group" in China, and carried out many businesses such as referral and in-hospital clinical decision support in China.
Recently, Huimei Medical Group established a new company-Huimei Jianyi Technology Co., Ltd., which aims to improve the medical and clinical level of doctors in China through a series of medical and service resources provided by Mayo Medical Group, and at the same time form a strategic partnership with many industry stakeholders represented by pharmaceutical companies to build an ecological platform in the Internet age.
Huimei Jianyi said that relying on Mayo's authoritative medical content and support, the company will cooperate extensively with the marketing department and medical department of pharmaceutical enterprises. Under the macro-policy environment that the country strongly advocates graded diagnosis and treatment and the development of primary medical services, the marketing and medical departments of pharmaceutical companies are increasingly aiming at delivering academic content to doctors, solving doctors' academic problems and improving doctors' medication level, rather than directly aiming at drug promotion, which is highly consistent with Huimei's purpose of helping to improve the clinical practice level of doctors in China by introducing Mayo's advanced medical content and clinical experience.
Tony Liu, CEO of Huimei Mobile Health Company, said: "It is our company's vision to provide academic services to doctors through information technology with Mayo resources as the core value and data science as the core competitiveness. "We have several core value assets from Mayo, such as AMC(Ask Mayo Clinic) system with intelligent consultation as the main scene, HIL(Health Information Library) system with more than 5,000 disease databases, and AME(Ask Mayo Expert) system. As well as a large number of patient teaching contents, online consultation mechanism between Dr. China and Dr. Mayo, and various summits and forums organized by Mayo, all these assets or services can carry out highly coordinated customer interaction with pharmaceutical companies to maximize the value of doctors, pharmaceutical companies and Hui Mei. "
According to Huimei Jianyi, Mayo brand has a very good brand recognition among doctors in China, especially in the first-line market. How to combine the brand effect with the needs of doctors at different levels and provide services is the company's primary task in the near future.
For example:
Regional KOL (key opinion leader) doctors need more international exposure and international exchanges, so the company can serve KOL by organizing various international activities with Mayo and various exchanges with Mayo doctors;
Directors and doctors who participate in the first-line market need to improve their regional influence, so the company provides all kinds of clinical thinking training based on AME, which not only meets the needs of doctors' professional development, but also improves the clinical ability of grassroots doctors through training activities;
For grass-roots doctors, such as county hospitals or community hospitals, they need to improve their actual clinical level, so all kinds of standard clinical pathways, intelligent consultation systems, disease databases and other information can help them;
Even for patients, the company can serve patients through the patient's educational content and intelligent self-test tools.
These can be combined with the business activities of pharmaceutical companies, such as the listing of new drugs, daily communication with target customers, teaching activities and so on. On the one hand, Hui Mei's authoritative academic content can complement the customer coverage ability of pharmaceutical companies, while Hui Mei provides disease, consultation and clinical pathways, and pharmaceutical companies can provide medication guidance, thus forming end-to-end medical academic services.
"All these doctors' needs for career development and academic services are also faced by pharmaceutical companies, especially the medical and marketing departments of pharmaceutical companies." Tony Liu said that with the same customer and market needs, there will be business opportunities for cooperation and strategic partnership. Whether it is the listing of new pharmaceutical products, expanding the vast market, going to the grassroots level, or even teaching patients, Huimin can provide strategic partner-level support. "
However, "we are not only satisfied with moving Mayo's brand and academics to China. We know that in the era of digitalization and big data, doctors need more and pharmaceutical companies need more. "
Before Huimei moved to Health, Tony Liu worked as a world-renowned service provider in many industries, such as the director of technology application and business transformation in IMS, a well-known industry consulting company, and the vice president in China in Veeva system. These technical and consulting experiences have enabled Tony Liu to focus on how to leverage Mayo's resources and realize the digital transformation of the industry.
It is reported that Huimei Mobile will release a platform product early next year. The platform aims to integrate the above-mentioned many doctor services, build an ecological platform to connect doctors, pharmaceutical companies and other industry stakeholders, and make it more convenient for pharmaceutical companies to serve doctors and doctors to receive information and services. "The most important thing is our data science ability, which is also our core competitiveness," Tony Liu said.
After entering the digital era, the value of data is increasing, but how to turn data into the core value that can drive enterprise strategy and business model is still beyond the power of many enterprises. In the process of serving doctors, migrant workers in Huimei will collect the collected data, relevant data provided by third-party partners and enterprise data that pharmaceutical companies are willing to provide, and use data science means such as machine learning to generate various prediction models for the doctors or patients they serve, and apply the output of such models to medical activities and marketing activities of pharmaceutical companies.
"Pharmaceutical companies used to rely on the theory of sales force effectiveness to guide their business activities, but in the digital age, we found that the traditional classic SFE theory in the western market needs some development and supplement, and we need a new theoretical framework that can cover the digital world to guide the business activities of enterprises. For example, in the digital world, how do enterprises define their target customers, how to differentiate and classify customers, and how to realize personalized content push of digital marketing. The answers to these questions can be answered by various algorithm models of data science and machine learning, such as clustering and decision tree. Although this road is still in the exploratory stage, the data of the medical industry is still in its infancy compared with other industries such as Fast Retailing, but we believe this will be the trend of the industry, and Huimei Jianyi hopes to lead the industry in this field. "
This is the corporate strategy of Huimei Medical, relying on Mayo's authoritative medical support, uniting pharmaceutical companies and other parties to create an industry transformation drive of "content", "data" and "informatization".
"Mayo has provided us with a good hand, but how to play this card well and make it recognized by doctors and enterprises needs our own ability to build it," Tony Liu said.
It is hoped that Huimei Mobile Health will adhere to the strategy and practice, provide the best service for doctors in China market, and really help the industry to complete the transformation and development in the new era.
About Mayo Medical Group
Mayo Clinic is one of the largest non-profit comprehensive medical groups in the United States with a history of 150 years. It is the most influential medical institution and represents the highest medical level in the world.
20 17 In August, US News and World Report published the ranking of American hospitals from 20 17 to 20 18. Mayo Clinic Rochester Campus ranked first with a total score of 4 15, far ahead of other well-known medical institutions. At the same time, among all 16 clinical departments, Mayo ranks first with 6 departments, second with 4 departments, third with 1 department and top ten with 4 departments, more than any other medical institution in the United States.
As the most reliable medical service organization, Mayo Clinic provides the best medical service to more than1.30 thousand patients from more than 1.40 countries around the world every year. Former American presidents Reagan, Ford, George H.W. Bush, Pan Shiyi and other political and business celebrities all made a special trip to treat diseases, which is recognized as the ultimate medical destination in the world. Former US President Barack Obama said, "Mayo is an outstanding representative of the best, most efficient and low-cost medical institutions in the United States, and should be an example for American medical reform to follow."
About Huimei Medical Group
Huimei Medical Group is a medical group company jointly funded by Mayo Clinic, a leading private non-profit medical institution in the United States, and Gaoling Capital, an investment company famous for its long-term structural value investment, 20 15.
Huimei Medical Group integrates medical investment, management, consultation and training, and comprehensively introduces Mayo's advanced knowledge, technology, management and training system applied to hospitals/clinics, doctors/nurses, patients and managers, and is committed to building a leading domestic composite platform for health information management, medical treatment and technology, and combining Mayo's top medical resources with the development needs of China's medical system to achieve the goal of creating a better medical experience for doctors and patients.
About Huimei Jianyi (Beijing) Technology Co., Ltd.
Huimei Jianyi is a subsidiary of Huimei Medical Group. Huimei Jianyi is committed to providing value to all stakeholders in the medical and health industry with Mayo's medical knowledge system and clinical practice as the core assets, data science as the core competitiveness and information technology as the means, and building an industry ecosystem by "connecting" all parties.
Through the long-term accumulation of its professional team members in the fields of medicine, Internet and big data, Huimei Jianyi Company combines data science, medical science, marketing science and information technology to provide products and services for health-related Internet industries such as medical treatment, patients and pharmaceutical enterprises.
Huimei's products and solutions include providing professional academic services to doctors through Mayo's resources and cooperation with pharmaceutical companies; Provide technical and data support for academic interaction between pharmaceutical companies and doctors by building an industry big data management platform; Provide various consulting services for digital multi-channel interaction between pharmaceutical enterprises and doctors and patients.